<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-158272</identifier>
<setSpec>0014-2565</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Recurrence risk of idiopathic venous thromboembolism</dc:title>
<dc:description xml:lang="en">For patients with idiopathic venous thromboembolism (unprovoked), the risk of recurrence is high. Secondary prophylaxis with anticoagulant therapy reduces the thrombotic risk but at the expense of an increased risk of haemorrhage. A number of factors, such as the male sex and an increase in dimer-D concentrations after completing the anticoagulation therapy, are associated with an increased risk of recurrence. Other factors such as residual venous thrombosis have a more controversial and sometimes contradictory relationship. A number of models have been proposed for predicting thrombotic recurrence risk after anticoagulation therapy in unprovoked TVD. However, these models need external validation to determine their current usefulness in clinical practice. In this article, we analyse the risk factors for thrombotic recurrence and the existing prediction models (AU)</dc:description>
<dc:creator>Ancos-Aracil, CL de</dc:creator>
<dc:creator>García-Navarro, MJ</dc:creator>
<dc:creator>Franco-Moreno, AI</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En pacientes con enfermedad tromboembólica venosa idiopática (no provocada) el riesgo de recurrencia es elevado. La profilaxis secundaria con terapia anticoagulante reduce el riesgo trombótico, pero a expensas de un incremento del riesgo de hemorragias. Algunos factores, como el sexo masculino o una elevación de la concentración de dímero-D tras finalizar la anticoagulación, se asocian a un mayor riesgo de recidiva; otros, como la trombosis venosa residual, tienen una relación más controvertida, incluso contradictoria. Se han propuesto algunos modelos de predicción del riesgo de recurrencia trombótica tras la anticoagulación en la ETEV no provocado, pero necesitan una validación externa para conocer su utilidad real en la práctica clínica. En este artículo se analizan los factores de riesgo de recidiva trombótica y los modelos de predicción existentes (AU)</dc:description>
<dc:source>Rev Clin Esp;216(9): 488-494, dic. 2016. tab</dc:source>
<dc:identifier>ibc-158272</dc:identifier>
<dc:title xml:lang="es">Riesgo de recurrencia en el tromboembolismo venoso idiopático</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d52618^s22054</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5678</dc:subject>
<dc:subject>^d52618^s22012</dc:subject>
<dc:subject>^d12428</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d33361^s22012</dc:subject>
<dc:subject>^d9951^s22012</dc:subject>
<dc:subject>^d52618^s22080</dc:subject>
<dc:subject>^d7336^s22073</dc:subject>
<dc:subject>^d28606</dc:subject>
<dc:subject>^d53393^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201612</dc:date>
</metadata>
</record>
</ibecs-document>
